Previous 10 | Next 10 |
NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...
2023-09-07 11:04:48 ET More on Lilly, Novo, etc. Novo Nordisk: Super Focused Pharma Company For The Long Run Novo Nordisk: Strong Fundamentals Meet Technical Uptrends Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad? Se...
2023-08-18 17:02:10 ET Gainers: Anavex Life Sciences ( NASDAQ: AVXL ) +10% . Palo Alto Networks ( PANW ) +9% . Fluence Energy ( FLNC ) +5% . Stronghold Digital Mining ( SDIG ) +4% . Zscaler ( ZS ) +4% . Losers: NAPCO ...
2023-08-17 18:42:16 ET Summary Taysha Gene Therapies has made significant progress with its gene therapy, TSHA-102, for the treatment of Rett Syndrome. Positive results were observed in the first patient treated with TSHA-102, showing improvement in key efficacy measures. The ...
2023-08-08 09:40:27 ET Anavex Life Sciences Corp. (AVXL) Q3 2023 Earnings Conference Call August 08, 2023, 08:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conferenc...
On track to release top-line data of potentially pivotal ANAVEX ® 2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half of 2023 Newly available preliminary efficacy results of surrogate biomarkers from the ANAVEX ® 2-73-AD-004 study in Alzheimer&...
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders ...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) shares. Investors, who purchased Anavex Life Sciences Corp. (NASDAQ: AVXL) shares prior to Februa...